Pramipexole — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Parkinson's Disease

• Amantadine
• Carbidopa-Levodopa
• Entacapone
• Ropinirole

Also listed for Restless Leg Syndrome

• Gabapentin
• Pregabalin

Other medications in Neurological

• Promethazine
• Propranolol
• Rasagiline
• Riluzole
• Rimegepant
• Risdiplam
• Rivastigmine
• Rizatriptan

What Pramipexole is approved for (FDA label)

PRAMIPEXOLE DIHYDROCHLORIDE tablets is a non-ergot dopamine agonist indicated for the treatment of • the signs and symptoms of idiopathic Parkinson's disease (PD) ( 1.1 ) 1.1 Parkinson's Disease Pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.

Source: Read the full FDA label on DailyMed. Label effective date: October 13, 2016.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Pramipexole (FDA label)

0.125 mg: white to off-white, round, flat, beveled edge uncoated tablets, debossed with 'SG' on one side '126' on other side. 0.25 mg: white to off white, oval, flat, beveled edge uncoated functional scored tablets debossed on one side with 'S' on the left side of bisect and 'G'on the right side of bisect and other side '1' on the left side and '27' on the right side of the bisect. 0.5 mg: white to off white, oval, flat, beveled edge uncoated functional scored tablets debossed on one side with'S' on the left side of bisect and'G'on the right side of bisect and other side'1'on the left side and '28' on the right side of the bisect. 0.75 mg: white to off white, oval, flat, beveled edge uncoated tablets, debossed with 'SG' on one side '129'on other side. 1.0 mg: white to off white, oval, flat, beveled edge uncoated functional scored tablets debossed on one side with 'S' on the left side of bisect and 'G' on the right side of bisect and other side '1' on the left side and '30' on the right side of the bisect. 1.5 mg: white to off white, oval, flat, beveled edge uncoated functional scored tablets debossed on one side with 'S' on the left side of bisect and 'G' on the right side of bisect and other side '1' on the left side and '31' on the right side of the bisect.

Source: FDA prescribing information (DailyMed). Set ID: a7405a56-de1c-4875-b57f-210c991474ba. SPL document ID: 540a17f8-b64d-41e1-a96b-d55bc8c48f3d. Label effective date: October 13, 2016. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Pramipexole (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: •Falling Asleep During Activities of Daily Living [see Warnings and Precautions (5.1)]. •Symptomatic Orthostatic Hypotension [see Warnings and Precautions (5.2)]. •Impulse Control/Compulsive Behaviors [see Warnings and Precautions (5.3)]. •Hallucinations [see Warnings and Precautions ( 5.4 )]. •Dyskinesia [see Warnings and Precautions ( 5.5)]. •Renal Impairment [see Warnings and Precautions (5.6)]. •Rhabdomyolysis [see Warnings and Precautions (5.7)]. •Retinal Pathology [see Warnings and Precautions ( 5.8)]. •Events Reported with Dopaminergic Therapy [see Warnings and Precautions (5.9)]. Most common adverse events (incidence >5% and greater than placebo): • Early PD without levodopa: nausea, dizziness, somnolence, insomnia, constipation, asthenia, and hallucinations ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: a7405a56-de1c-4875-b57f-210c991474ba. SPL document ID: 540a17f8-b64d-41e1-a96b-d55bc8c48f3d. Label effective date: October 13, 2016. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Pramipexole (FDA label)

• Falling asleep during activities of daily living: Sudden onset of sleep may occur without warning. Advise patients to report symptoms to the prescriber. ( 5.1 ) • Symptomatic orthostatic hypotension. Monitor during dose escalation ( 5.2 ) • Impulse control/Compulsive behaviors: Patients may experience compulsive behaviors and other intense urges ( 5.3 ) • Hallucinations: May occur. Risk increases with age. ( 5.4 ) • Dyskinesia: May be caused or exacerbated by PRAMIPEXOLE DIHYDROCHLORIDE tablets ( 5.5 ) • Renal Impairment: Requires dose reduction ( 2.2 , 12.3 ) • Events reported with dopaminergic therapy: Include withdrawal-emergent hyperpyrexia and confusion, fibrotic complications, and melanoma ( 5.9 ) 5.1 Falling Asleep During Activities of Daily Living Patients treated with pramipexole have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles which sometimes resulted in accidents.

Source: FDA prescribing information (DailyMed). Set ID: a7405a56-de1c-4875-b57f-210c991474ba. SPL document ID: 540a17f8-b64d-41e1-a96b-d55bc8c48f3d. Label effective date: October 13, 2016. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Pramipexole (FDA label)

See also Dosage and Administration (2.2) and Clinical Pharmacology ( 12.3 ) Dopamine antagonists may diminish the effectiveness of pramipexole ( 7.1 ). 7.1 Dopamine Antagonists Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of pramipexole dihydrochloride tablets. 7.2 Drug/Laboratory Test Interactions There are no known interactions between pramipexole and laboratory tests.

Source: FDA prescribing information (DailyMed). Set ID: a7405a56-de1c-4875-b57f-210c991474ba. SPL document ID: 540a17f8-b64d-41e1-a96b-d55bc8c48f3d. Label effective date: October 13, 2016. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.